Allergy Therapeutics (Canada) Ltd. is voluntarily withdrawing these products from the Canadian market. While these products have been sold for more than 10 years regulatory data have never been submitted for review. The necessary data is being collected, but until such time as Health Canada reviews this data and grants appropriate regulatory approval, these products will no longer be available. Allergy Therapeutics (Canada) has never received any adverse reactions respecting Pollinex T or Pollinex G, however, physicians may wish to evaluate the risk benefit to patients prior to continuing any therapy which has already been initiated.

(Note: This does not apply to Pollinex R for ragweed immunotherapy)